Mainstream

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Post Contentorka, abbvRead More

You might also be interested in reading Weak Wave, But Strong Intent: BNB Bulls Poised To Challenge The $1,300 Zone.

September 17, 2025
In Mainstream